Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

NRx Pharmaceuticals (NASDAQ: NRXP) , via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a ...

NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics (TM), Inc., has signed a binding Letter ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

No, Spravato isn’t approved by the Food and Drug Administration (FDA) to treat anxiety or bipolar disorder. But in some cases, doctors may prescribe the drug off-label for these uses.

Spravato should be used in conjunction with an oral antidepressant, according to both the FDA and Janssen. The FDA said this is the first time esketamine was approved for any use.

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...